Novel Dome-shaped Hydrogel Sensor
GlucoSet AS develops tools for accurate continuous glucose monitoring in Intensive Care Units, to reduce patient mortality and hospital costs. GlucoSet has developed a disruptive sensor that allows physicians in the ICU to accurately monitor blood glucose levels in real-time, enabling better therapeutic decisions. Built on a strong IP portfolio and an established technology, GlucoSet is an intravascular optical fibre sensor – with unrivalled user-friendliness and portability – designed to be inserted through an artery catheter already installed in most ICU patients and without disrupting the current use of that catheter.
Innovayt assisted GlucoSet with the writing and development of the proposal that was approved for funding by the EU Horizon 2020 SME Instrument Phase 1. This grant will allow the company to perform a feasibility study in order to quantify GlucoSet’s competitive advantages, market potential, validate and specify a clinical and regulatory strategy.
Nicolas Elvemo, General Manager of GlucoSet, says: “When we were looking for a grant application consultancy, our primary concern was that they would take the upfront fee and not contribute to actually making the application succeed. We never regretted picking Innovayt; their long-term view on achieving results ensures our interests are aligned with theirs, which is key to why we succeeded together.
I really enjoyed the fact that Eduardo acted like a project manager and frequently asked for more information. I think the informal and very frequent, often more than daily, communication was key to us finishing such a good application in such a short time.”